Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17682206 | 0.85 | HRH2 (0.35) | GAAALDH1A1CYP1A2HRH2HRH1 | |
| SCHEMBL30036393 | 0.85 | ALDH1A1 (0.37) | GAAALDH1A1HPGDTSHRMAPT | |
| SCHEMBL261444 | 0.84 | HRH2 (0.38) | GAAALDH1A1CYP1A2HRH2HRH1 | |
| SCHEMBL25301498 | 0.82 | HRH2 (0.39) | GAAALDH1A1CYP1A2HRH2HRH1 | |
| SCHEMBL290148 | 0.81 | ALDH1A1 (0.37) | GAAALDH1A1HPGDTSHRFBP1 | |
| SCHEMBL280483 | 0.77 | GAA (0.33) | GAAALDH1A1CYP1A2HRH2HRH1 | |
| SCHEMBL27860995 | 0.75 | PTGDR2 (0.36) | GAAALDH1A1CYP1A2HRH2HRH1 | |
| SCHEMBL259210 | 0.75 | GAA (0.34) | GAAALDH1A1MAPTRAB9A | |
| SCHEMBL261442 | 0.74 | SRC (0.47) | CYP1A2HRH2HRH1HRH4SRC | |
| SCHEMBL263398 | 0.74 | ALDH1A1 (0.45) | GAAALDH1A1CYP1A2HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753734-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2007-02-21 | — | — | EP | claimed |
| WO-2005105765-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2005-11-10 | — | — | WO | claimed |
| WO-2025210159-A3 | CELL FACTORY FOR PRODUCTION OF SULFUROL | BIOSYNTIA APS (DK) | 2025-11-20 | — | — | WO | disclosed |
| WO-2025210159-A2 | CELL FACTORY FOR PRODUCTION OF SULFUROL | BIOSYNTIA APS (DK) | 2025-10-09 | — | — | WO | disclosed |
| US-20150218597-A1 | USE OF THIAMINE AND NICOTINE ADENINE DINUCLEOTIDE FOR BUTANOL PRODUCTION | BUTAMAX ADVANCED BIOFUELS LLC (US) | 2015-08-06 | — | — | US | disclosed |
| US-9012190-B2 | Use of thiamine and nicotine adenine dinucleotide for butanol production | BUTAMAX ADVANCED BIOFUELS LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-20120323047-A1 | USE OF THIAMINE AND NICOTINE ADENINE DINUCLEOTIDE FOR BUTANOL PRODUCTION | BUTAMAX(TM) ADVANCED BIOFUELS LLC (US) | 2012-12-20 | — | — | US | disclosed |
| US-8134010-B2 | 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease | RENOPHARM LTD. (IL) | 2012-03-13 | — | — | US | disclosed |
| US-7968575-B2 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2011-06-28 | — | — | US | disclosed |
| US-7579477-B2 | Thiazole-based nitric oxide donors having alkyl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2009-08-25 | — | — | US | disclosed |
| US-7498445-B2 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2009-03-03 | — | — | US | disclosed |
| US-7189750-B2 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2007-03-13 | — | — | US | disclosed |
| EP-1753734-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2007-02-21 | — | — | EP | disclosed |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2007-01-25 | — | — | US | disclosed |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
| WO-2005105765-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | NOS2, NOS1, NOS3 | GAA 1805/4885ALDH1A1 274/4885CYP1A2 138/4885 |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | NOS2, NOS1, NOS3 | GAA 1359/4885ALDH1A1 202/4885CYP1A2 46/4885 |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | NOS2, NOS1, SQOR | GAA 1946/4885ALDH1A1 240/4885CYP1A2 164/4885 |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | NOS2, NOS1, NOS3 | GAA 1630/4885ALDH1A1 337/4885CYP1A2 143/4885 |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | NOS2, NOS1, NOS3 | GAA 1722/4885ALDH1A1 475/4885CYP1A2 168/4885 |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | NOS1, NOS2, NOS3 | GAA 2875/4885ALDH1A1 204/4885CYP1A2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.